Uncategorized

Sanofi suspends chronic lung disease phase 2 study, tied to ‘strategic business reasons’

Published

on

Sanofi halted a phase 2 trial testing a monoclonal antibody, SAR445399, in non-cystic fibrosis bronchiectasis, Fierce has learned.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version